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Acute necrotizing encephalopathy (ANE) is a rapidly progressive encephalopathy that can occur in otherwise healthy children after
common viral infections such as inﬂuenza and parainﬂuenza. Most ANE is sporadic and nonrecurrent (isolated ANE). However, we iden-
tiﬁed a 7 Mb interval containing a susceptibility locus (ANE1) in a family segregating recurrent ANE as an incompletely penetrant, auto-
somal-dominant trait. We now report that all affected individuals and obligate carriers in this family are heterozygous for a missense
mutation (c.1880C/T, p.Thr585Met) in the gene encoding the nuclear pore protein Ran Binding Protein 2 (RANBP2). To determine
whether this mutation is the susceptibility allele, we screened controls and other patients with ANE who are unrelated to the index
family. Patients from 9 of 15 additional kindreds with familial or recurrent ANE had the identical mutation. It arose de novo in two fami-
lies and independently in several other families. Two other patients with familial ANE had different RANBP2 missense mutations that
altered conserved residues. None of the three RANBP2missense mutations were found in 19 patients with isolated ANE or in unaffected
controls. We conclude that missense mutations in RANBP2 are susceptibility alleles for familial and recurrent cases of ANE.Introduction
With the proliferation of genetic tools, both hosts and
pathogens have been studied for genomic changes that
account for variation in disease susceptibility and
severity.1,2 Disorders in which hosts respond abnormally
to common illnesses provide an additional paradigm for
understanding environmentally triggered diseases. In one
such host-mediated disorder, acute necrotizing encepha-
lopathy (ANE), previously healthy children develop44 The American Journal of Human Genetics 84, 44–51, January 9,encephalopathy, seizures, and coma within days after the
onset of a common childhood febrile infection, such as
inﬂuenza A or parainﬂuenza,3 without evidence of viral
infection of the brain or inﬂammatory cell inﬁltration.4
Brain T2-weighted MRI reveals characteristic symmetric
lesions present in the thalami, pons, and brainstem.
Initially reported in Japan and Taiwan, ANE affects chil-
dren worldwide.5 The fact that different infections can
produce the same phenotype suggests that the disorder is
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be more adept at triggering the host response.2 Increased
serum and CSF levels of IL-6 and TNF-a have been reported
in children with ANE,6,7 leading to the prevailing hypoth-
esis of a ‘‘cytokine storm’’ as part of the pathogenic mech-
anism.4 Morbidity and mortality are high.4
We reported a family in which the predisposition to
developingANE segregates as an autosomal-dominant trait,
previously abbreviated as ADANE (HGNC: ANE1, OMIM
608033).8 In this family, 16 family members manifested
clinical symptoms of ANE and diagnosis was conﬁrmed by
pathologic examination in two affected children who had
died from their illnesses. Penetrance was estimated at 40%
and recurrent episodes occurred in half of the affected indi-
viduals. We mapped the ANE1 locus to a 7 million basepair
region on chromosome 2q.9 We now report that heterozy-
gous missense mutations in the gene RANBP2, which
encodes the nuclear pore component Ran Binding Protein
2, account for genetic susceptibility to ANE in this family
and in many other patients with familial or recurrent ANE.
Methods and Materials
Study Subjects
Individuals from 35 unrelated families participated in this study.
Nineteen individuals of European (7), Asian (10), or African
descent (2) had isolated ANE. The remaining individuals came
from 16 families of European descent affected by familial or recur-
rent ANE. The diagnosis of ANE was based upon the following
three criteria: (1) a rapidly progressive encephalopathy beginning
1 to 3 days after the onset of a febrile illness; (2) MRI imaging
demonstrating multifocal symmetric lesions of the brain speciﬁ-
cally involving the thalamus, but with lesions of the midbrain,
pons, and brainstem viewed as supportive; and (3) clinical and
laboratory exclusion of meningitis, encephalitis, inborn errors of
metabolism, and toxin exposure. Familial or recurrent forms of
ANE required at least one of these additional criteria: (1) a relative
with conﬁrmed ANE, (2) a relative with a history of unexplained
CNS dysfunction occurring in the context of concurrent febrile
illness or recent infection, or (3) recurrence of ANE in the proband.
We obtained informed consent, approved by the University
Hospitals of Cleveland Institutional Review Board, from all partic-
ipants. Blood was collected for DNA extraction and for the crea-
tion of EBV-transformed lymphoblasts by standard methods.
Ethnically matched controls were taken from 200 control DNA
samples, from healthy individuals with self-reported European
ancestry, and from 184 European neurologically normal controls
(NINDS control panels NDPT009 and NDPT021, Coriell Reposito-
ries, Camden, NJ). An additional 1000 controls were taken from
the CEPH genome diversity panel.
1297 subjects with multiple sclerosis (MS [OMIM 126200]) and
549 controls were enrolled under a study protocol approved by the
Partners Healthcare Institutional Review Board of each institution.
Subjects with MS all meet McDonald criteria for MS.10 A summary
of the clinical composition of the collection of subjects is given in
Table S1 available online.
High-Throughput Sequencing
Genomic DNA from four members of the original ADANE
kindred9 was used for high-throughput sequencing; this includedThe Atwo affected individuals with the linked haplotype and two unaf-
fected individuals without the linked haplotype. Exon sequences,
including 300 bp of ﬂanking intron, were extracted from the
human genome assembly. PCR primers were designed ﬂanking
the exons of genes of interest via the program primer311 and
purchased from Invitrogen (Carlsbad, CA) in 96-well plates. Sufﬁ-
cient ﬂanking sequence was included to interrogate splice sites as
well as coding exons. PCR was performed with 100 ng genomic
DNA, 1 mM primer, and Taq Gold Polymerase kits from Applied
Biosystems (Foster City, CA) in 10 ml total reaction volume in
384-well plates. Prior to sequencing (Applied Biosystems BigDye
v1.1), PCR products were treated with Exonuclease I and shrimp
alkaline phosphatase (USB Corporation, Cleveland, OH). Bidirec-
tional sequence data, with the initial PCR primers, was obtained
on an Applied Biosystems 3730xl DNA Analyzer. Sequences were
assembled with phred and phrap and visualized with the consed
software package.
Reverse Transcription PCR of RANBP2
Total RNAwas extracted from EBV-transformed lymphoblasts with
TRIzol (Invitrogen) according the manufacturer’s protocol. First-
strand synthesis was performed with Superscript III (Invitrogen)
with a RANBP2-speciﬁc primer (50-AGCAAATCTTTAACGAAA
GAAC-30) that is complementary to a unique sequence within
the transcript’s 30UTR. The cDNA was then PCR ampliﬁed and
sequenced (Table S2).
Ampliﬁcation of Exons 12 and 14 from RANBP2
via Genomic DNA
Primers, PCR conditions, and internal sequencing primers were
designed to speciﬁcally interrogate RANBP2 and not the related
paralogs that are found in segmental duplications (Table S3).
Denaturing High-Performance Liquid
Chromatography Screening for the RANBP2
c.1880C/T Variant via the Human Diversity Panel
Members of the original ANE kindred who were either homozy-
gous wild-type or heterozygous for the c.1880C/T variant were
used to deﬁne the following parameters on the Transgenomic
WAVE D7000 (Transgenomic, Omaha, NE) that could identify
c.1880C/T heterozgyotes via 5 ml of the exon 12 amplimer
(temperature 57C, initial B% ¼ 55, ﬁnal B% ¼ 61, gradient 2%
B/minute). DNA aliquots from the human genome diversity panel
were provided by Jeffrey Murray and Hatem el-Shanti.
Deﬁning Haplotypes that Contain the c.1880C/T
Mutation
PCR primers were designed to amplify and sequence contiguous
intragenic genomic DNA fragments upstream and downstream
of c.1880C/T mutation in exon 12 of RANBP2 to ﬁnd additional
informative SNPs (Table S3). Phase of the SNPs relative to
c.1880C/T was determined by evaluating probands, siblings,
and parents.
Families that were not informative for intragenic SNPs were
analyzed for previously described microsatellite markers (UCSC
genome browser) that map from 0.115 to 3.2 Mb from RANBP2.
HEX- or FAM-labeled PCR primers in a standard PCR reaction
were analyzed on an ABI prism 3700, with the GenoTyper soft-
ware. Primer sequences for markers of the D2S- designation are
publicly available (UCSC genome broswer). Primer sequences formerican Journal of Human Genetics 84, 44–51, January 9, 2009 45
the STR88 marker are (50HEX-CAGTGGTTGACCTCCTGACC-30)
and (50-CCAGGATGAAGCAGAGGAA-30).
Genotype Screening in aMultiple Sclerosis Population
RANBP2 was genotyped for one susceptibility allele, the T or C at
c.1880, via the hME Sequenom MassARRAY platform (Sequenom,
San Diego, CA). These data generated met standards for high-
quality data (>95% genotype call rate, HWE p value > 0.001) in
healthy control subjects. The RANBP2 assay consisted of two
extension primers: 50-AGCGGATAACTTTTAGACCTGGAAACGTA
GCA-30 and 50-AGCGGATAACAAGGCTGACCATCTACACCTC-30
for an amplicon length of 522 bp. The detection primer had the
following sequence: 50-CAGAATGCCTTCAGAAAA-30. The PCR
parameters were as follows: 5 min at 95C, 39 cycles of 1 min at
94C, 50 s at 63C, and 50 s at 72C, followed by 10 min at
72C, then hold at 10C.
Results
Thirty-ﬁve unrelated patients or families affected by ANE
participated in this study. Sixteen probands had familial
or recurrent ANE (Figure 1) and 19 had isolated ANE.
At the initiation of this study, only one family with
a clear genetic susceptibility to ANE had been identiﬁed.
DNA from this family had been used to deﬁne a 7 Mb
Figure 1. Pedigrees of 16 Families with
Familial or Recurrent ANE
Pedigrees with mutations in RANBP2 are
given in (A) whereas those without muta-
tion are shown in (B). Family numbers are
given at top. Symbol notations for (A) as
follows: filled, mutation carrier, affected
with ANE; filled with white lower right
quandrant, mutation carrier, recurrent
ANE; vertical bar, mutation carrier; hori-
zontal bar, encephalopathy, unconfirmed
as ANE; underlined symbol, DNA studied;
circled symbol, molecularly proven de
novo mutation carrier. For simplicity, not
all siblings and spouses are shown in pedi-
gree 586. Symbol notations for (B) are
equivalent to (A) except without mutation.
candidate interval.9 Exons of all
known genes, predicted genes, and
spliced ESTs within the interval were
sequenced with DNA from two
affected and two unaffected family
members. No disease-causing muta-
tion was identiﬁed. However, 117
out of 363 exons failed sequencing
because they are part of large
segmental duplications. These seg-
mental duplications (Figure 2A)
contain sequence derived from
RANBP2 and a trans-Golgi compo-
nent, Grip coiled-coil domain-con-
taining protein 2 (GCC2). RANBP2 and GCC2 underwent
a partial duplication and genomic rearrangement to form
a novel gene encoding ‘‘RANBP2-like and GRIP Domain-
containing protein’’ (RGPD). RGPD subsequently under-
went further genomic duplication in the human and chim-
panzee progenitor to produce a total of eight RGPDs
(RGPD1-8).12,13 The strong conservation of genomic orga-
nization (Figure 2B) and sequence between RANBP2 and
RGPDs 1-8 initially limited the ability to reliably interro-
gate these genes with genomic DNA.
To sequence RANBP2, we therefore used gene-speciﬁc
primers and performed RT-PCR with mRNA derived from
patient lymphoblasts (Figure 2B). This led us to identify
a heterozygous C/T transition at position 1880 of the
cDNA (c.1880C/T), which is predicted to cause an amino
acid substitution (p.Thr585Met) (Figures 2C and 2D). All
affected family members and obligate carriers are heterozy-
gous for this mutation.We did not observe themutation in
384 control DNAs from individuals with self-reported
European ancestry or in 1000 DNAs from the human
genome diversity panel.
We then screened RANBP2 in 15 additional families sus-
pected of having familial or recurrent ANE and found 9
with the same heterozygous c.1880C/T mutation. In46 The American Journal of Human Genetics 84, 44–51, January 9, 2009
Figure 2. Mutation Identification in
RANBP2
(A) The locations and orientations of
RANBP2, GCC2, and the RGPDs are shown
on a partial ideogram of chromosome 2.
(B) A comparison of the genomic regions of
RANBP2 and RGPD5 indicating strong struc-
tural and sequence conservation for their
exons 1-18 (upper lines) and the diver-
gence of their 30 regions (lower lines).
RGPD5 is deleted for a portion of exon 20
and has its final three exons derived from
GCC2 (shaded box). This enables RANBP2-
specific cDNAtobe synthesizedwith aprimer
(hollow arrow) in the gene’s 30UTR. Also
shown is the location of the c.1880C/T
mutation in exon 12 of RANBP2 (arrow-
head).
(C) Sequencing electropherograms of
RANBP2-specific cDNA reveals a c.1880C/T
transition in the patient but not the
control.
(D) Intronic primers that amplify exon 12 of
RANBP2 and the RGPD paralogs (upper two
electropherograms) demonstrate multiple
paralog-derived signal alterations (arrow-
heads) in the patient and the control. In
contrast, sequence specific to exon 12 of
RANBP2 (lower electropherograms) shows
the absence of paralog-derived signals
in the patient and control, but persistence
of the c.1880C/T mutation (arrow) in
the patient.
(E) Schematic diagram of RANBP2 protein
indicating the ‘‘leucine-rich’’ domain (LD),
four Ran binding domains (RBD), eight
zinc finger repeats (ZnF), a cyclophilin A
domain (CyA), and a SUMO E3 ligase domain
(E3). In the partial deletion of the 20th
exon, the RGPDs lose the ZnF and second
RBD domain. The derived exons from GCC2 provide a new C-terminal GRIP domain which targets the RGPDs to the Golgi. The sites of the
p.Thr585Met, p.Thr653Ile, and p.Ile656Val LD domain substitutions associated with ANE1 are indicated by arrows.2 of these 9 families (pedigrees 100 and 121, Figure 1), the
mutation arose de novo. Six other families did not share
a common linked haplotype (Figure 3), indicating addi-
tional independent origins for this mutation. Two families
(pedigrees 671 and 613, Figure 1) did not have the
c.1880C/T mutation, but were heterozygous for other
missense mutations in RANBP2 (either c.2085C/T;
p.Thr653Ile or c.2094A/G; p.Ile656Val). These mutations
also altered highly conserved residues and were not
observed in 200 controls. Finding de novo and indepen-
dently arising missense mutations in affected families,
and not in controls, clearly implicates RANBP2 as a suscep-
tibility allele for familial or recurrent ANE.
RANBP2 mutations were not found in 4 of the 15 addi-
tional families. Linkage to RANBP2 could be excluded by
haplotype analysis in one family (108, Figure 1). In
another, parental consanguinity, multiple affected chil-Thedren, and lack of family history suggests recessive inheri-
tance (611, Figure 1). Although RANBP2 missense muta-
tions are not the sole susceptibility alleles for familial or
recurrent ANE, they accounted for 75% (12 of 16) of the
familial or recurrent cases in this series. In light of the
potential locus heterogeneity, we propose using the term
‘‘ANE1’’ when disease is associated with a RANBP2
missense mutation.
We did not ﬁnd RANBP2 mutations in the 19 patients
who had isolated ANE, indicating that ANE1 is etiologi-
cally distinct. We initially relied on family history or
disease recurrence to differentiate familial from isolated
ANE. Having found a mutation, we could determine
whether patients with ANE1 had other features that may
distinguish them from patients with isolated ANE. As
with isolated ANE, infection was the antecedent of neuro-
logic deterioration in ANE1. Speciﬁc infectious agentsAmerican Journal of Human Genetics 84, 44–51, January 9, 2009 47
Figure 3. Comparison of Mutation-
Bearing Haplotypes in Seven Families
with c.1880C/T Mutation
The haplotypes of seven families show
differences in intragenic and extragenic
polymorphic markers, suggesting indepen-
dent origins for each family of the linked
c.1880C/T mutation. Alleles are shown
in their contiguous arrangement and
represented as STR PCR fragment size
(e.g., D2S2229), nucleotide allele (e.g.,
rs826559), or repeat count (ss76880141).
Marker distances are given relative to the
c.1880C/T mutation site (0 Kb), with
orientation along the plus strand of the
chromosome. RANBP2 intragenic markers
are delineated between horizontal lines at
4.1 Kb and þ25.8 Kb. To highlight the
potential for, or lack of, ancestral relation-
ship, matching alleles are given the same
unique color. When noninformative, both
alleles are shown (e.g., family 102,
D2S293).implicated in 10 of 28 ANE1 episodes include inﬂuenza A
(7 episodes), inﬂuenza B (1 episode), parainﬂuenza II
(1 episode), and Mycoplasma pneumoniae (1 episode).
Similar to isolatedANE, patientswithANE1had ahigh inci-
dence of seizure (59%), coma (100%), and CSF protein
elevation (85%). Unlike patients with isolated ANE, 82%
of whom have been reported to have elevations of serum
transaminases,3 no elevation was observed in patients
with ANE1. Also unusual for isolated ANE, which affects
young children, three patientswithANE1haddisease onset
during adolescenceor adulthood (ages 12, 14, and37years).
Our inclusion criteria for ANE required MRI showing
symmetric alterations of the thalami, with lesions of the
brainstem and pons viewed as supportive for the diagnosis
(Figure 4). Although each ANE1 patient demonstrated this
pattern at least once, recurrent episodes revealed vari-
ability in presentation, with the thalami being affected in
16 of 17 initial and 7 of 9 recurrent episodes (17 patients).
The pons was affected frequently (23 of 26 total episodes)
and lesions of the medulla were less common (8 of 26
episodes). Patients with ANE1 also had involvement of
additional CNS structures, including the external capsule
and claustrum (19 of 26 episodes), medial temporal lobes
and limbic structures including amygdalae, hippocampi,
or medial temporal lobes (19 of 26), and spinal cord (3 of
26 episodes). These additional sites have not been previ-
ously reported in patients with isolated ANE.
Two families in our study reported a positive family
history for demyelinating disease suggestive of multiple
sclerosis, of whom one was a carrier of the c.1880C/T
mutation. However, the carrier of the c.1880C/T muta-
tion had a brain MRI that was more suggestive for ANE
(G.D., unpublished data). This indicated that some adults
with manifestations of ANE1, especially if recurrent, could48 The American Journal of Human Genetics 84, 44–51, January 9,be misdiagnosed with MS. We tested a well-characterized
cohort of 1297 MS patients and 547 accompanying
controls for the c.1880C/T mutation to determine
whether rare patients diagnosed with MS might have actu-
ally had adult-onset ANE1.We did not ﬁnd the c.1880C/T
mutation in any MS cases or controls. Thus, according to
stringent diagnostic criteria for MS,14 c.1880C/T does
not contribute to this disease. It remains to be determined
whether genetic risk factors that predispose to MS alter
the penetrance of ANE1.
Discussion
We have identiﬁed a missense mutation in RANBP2 as
a genetic risk factor for an environmentally triggered
neurologic disease, ANE1. The c.1880C/T allele occurred
de novo in two patients and arose independently in several
families. Two other missense alleles, which were found in
single families, require further study to demonstrate their
role in ANE1 susceptibility. RANBP2 is not the sole suscep-
tibility gene for ANE, as indicated by the fact that we did
not ﬁnd mutations in 4 of 16 kindreds with familial or
recurrent disease or in patients who had isolated ANE.
Nevertheless, the unexpected ﬁnding that a missense
mutation in a component of the nuclear pore predisposes
individuals to infection-triggered neurologic disease opens
new avenues of research.
RANBP2 is a 358 kD protein located on the cytoplasmic
surface of the nuclear pore.15 It has numerous roles
throughout the cell cycle. During interphase, its nuclear
envelope-associated functions include facilitation of
protein import and export and sumoylation of protein
cargoes.16 However, in certain cell types including2009
neurons, it is detected associated with microtubules17 and/
or mitochondria,18,19 suggesting roles in intracellular traf-
ﬁcking or energy maintenance. During mitosis, RANBP2 is
important for nuclear envelope breakdown20 and it local-
izes to the kinetochore,21 where it facilitates sister chro-
matid resolution.22
We do not know whether the RANBP2mutations predis-
pose to disease by disrupting one of the protein’s many
endogenous functions or by creating a novel biologic
activity. Support for the latter possibility derives from
a comparison between the RANBP2 protein sequence,
which is part of the nuclear pore complex, and the eight
RGPD proteins, which localize to the trans-Golgi appa-
ratus.13 The mutated amino acid residues p.Thr585,
p.Thr653, and p.Ile656 are conserved in all mammalian
RANBP2 proteins. In contrast, the p.Thr585Met amino
acid substitution is present as a stable variant in four of
the eight RGPDs, which have undergone further positive
selection for sequence divergence.13 These trans-Golgi
localized proteins likely have altered biologic properties
in their new context, and amino acid changes that confer
selective advantage in the RGPDsmay be deleterious to the
original RANBP2. The fact that the p.Thr585Met RANBP2
substitution occurred de novo twice and was found in
two thirds of familial or recurrent ANE cases, and not in
3230 controls or non-ANE subjects, supports this notion.
Figure 4. Brain MRI Findings in a Child (690,
II:1) with Familial and Recurrent Acute Necro-
tizing Encephalopathy
T2-weighted images obtained during the acute
encephalopathy (top) are shown in comparison to
resolved images obtained 6 months later (middle)
and images from a recurrent episode 3 years later
(bottom). During acute events, abnormal signal is
visible in the pons (white arrow), midbrain (thin
white arrow), amygdala (black arrow), thalamus
(black arrowhead), and external capsule (white
arrowhead).
Mutations in RANBP2 predispose to ANE1,
but by themselves are insufﬁcient to make
the phenotype fully penetrant. Therefore,
additional genetic and environmental factors
are required. Infection precedes episodes of
neurologic deterioration. However, neither
the infectious agent nor the individual’s
genetic background fully explains the incom-
plete penetrance or episodic nature of this
disease. For example, the neurologic responses
during the same viral illness were often discor-
dant in a pair of identical twins (pedigree 586)
with the c.1880C/T mutation. Environ-
mental factors such as differences in viral inoc-
ulum, route of viral exposure (oral versus intra-
nasal),23 and nutritional state could play
a role. If the amino acid substitutions result
in temperature sensitivity, resulting in protein misfolding
and alteration of function, variations in the severity and
duration of fever could contribute to the reduced pene-
trance. Alternatively, the somatic recombinations and
mutations that create the diversity present in immuno-
globulins and T cell receptors may also provide a source
of variation for the initiation of ANE1.24
At present, the complex roles of RANBP2make it difﬁcult
to speculate on the mechanism of the mutational effect.
The three mutations identiﬁed cluster in the ‘‘leucine-
rich domain’’ (LD) that has been described as a domain
necessary for localization to the both the nucleus and
microtubules.17 However, the p.Thr585Met mutation
occurs outside of the subregion of the LD associated with
nuclear association,17 suggesting that the mutational
effect could impact its interaction with microtubules.
The lesions of necrotizing encephalopathy suggested the
involvement of energy metabolism, because it involves
the same constellation of pathological ﬁndings described
in Wernicke encephalopathy (associated with thiamine
deﬁciency; [OMIM 277730]) and Leigh syndrome (which
can be due to various defects of mitochondrial ATP produc-
tion; [OMIM 256000]).3 We previously reported a coupling
defect of oxidative phosphorylation in one of the ANE1
cases.8 RANBP2 has recently been shown to contribute to
the subcellular distribution of mitochondria through itsThe American Journal of Human Genetics 84, 44–51, January 9, 2009 49
kinesin-binding domain.18 Mice haploinsufﬁcient for
RanBP2 have reduced amounts of brain hexokinase19 and
altered lipid metabolism.25 Age-related defects in free fatty
acid uptake lead to impaired weight gain and resistance of
retinal cells to apoptosis.25 Thus, intracellular trafﬁcking of
mitochondria, energy production, and lipid peroxidation
are potential targets for RANBP2 mutational effects.
However, other processes that could be affected by RANBP2
mutations include viral entry, antigen presentation, cyto-
kine signaling, immune responsiveness, and blood-brain
barrier maintenance. Studies at the cell-biologic and
whole-organism levels will be required to delineate the
effects of RANBP2 mutations.
Our study was not designed to prospectively ascertain all
patients who have been diagnosed with ANE. Therefore,
we cannot yet estimate the frequency of ANE1 among
unselected individuals with ANE. Clinical features in
ANE1 substantially overlap those of isolated ANE,
although lesions occurring outside of the brainstem and
thalamus and normal serum transaminase levels may
help clinically differentiate the two. At present we suggest
that ANE1 be considered in the differential diagnosis of
any patient with ﬁndings consistent with ANE and (1)
family history of neurologic symptoms occurring in the
context of infection, (2) recurrent disease, or (3) MRI
changes of ANE that affect the external capsule, claustrum,
limbic structures, or temporal lobes. In order to prevent or
lessen the neurologic consequences of ANE1, it remains
important to determine how missense mutations in
RANBP2 predispose to CNS dysfunction.
Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.ajhg.org/.
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